Swedish Boost For Life Sciences Innovation Resonates Around Europe
This article was originally published in The Pink Sheet Daily
Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.
You may also be interested in...
FDA commissioner says all stakeholders need to come to the table to develop a path for maintaining U.S. preeminence in making medical discoveries and moving them through the pharmaceutical pipeline into patients’ hands.
Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.